|
|
|
|
|||||
|
|
|
AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trending on Wednesday.
Shares of the Vancouver-based biotechnology company rose 9.32% in after-hours trading on Tuesday to $3.52 after the company reported its fourth-quarter 2025 earnings.
AbCellera Biologics posted earnings per share of negative $0.03, compared with an estimate of negative $0.18, representing an 83.33% earnings outperformance.
Its revenue also increased by $39.80 million from a year earlier.
The fourth-quarter results follow a challenging third quarter of 2025, when ABCL missed earnings per share estimates by $0.02.
AbCellera Biologics has a market capitalization of $963.86 million, with a 52-week high of $6.52 and a 52-week low of $1.89.
It has a Relative Strength Index (RSI) of 44.92.
The stock of the clinical-stage company has delivered a 14.18% gain over the past 12 months.
Price Action: ABCL closed on Tuesday up 6.27% at $3.22, according to Benzinga Pro data.
The stock is about 28.7% above its 52-week low, closer to the lower end of its annual range.
Benzinga's Edge Stock Rankings indicate that ABCL has a negative price trend across all time frames.
Photo courtesy: santima.studio / Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
| 3 hours | |
| 7 hours | |
| Feb-24 | |
| Feb-24 | |
| Feb-24 | |
| Feb-19 | |
| Feb-18 | |
| Feb-11 | |
| Feb-02 | |
| Jan-29 | |
| Jan-22 | |
| Jan-14 | |
| Jan-12 | |
| Dec-08 | |
| Dec-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite